Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B
Open Forum Infectious Diseases · 27.11.2024 · 11 (12)
DOI: 10.1093/ofid/ofae699 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 27.11.2024. Verfasst von Wei-Fan Hsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Background
The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleos(t)ide analogue (NA) therapy remains unclear. We delineated the kinetics of HBsAg and analyzed its association with long-term treatment outcomes.
Methods
We enrolled 912 treatment-naïve patients with chronic hepatitis B (CHB) who had received NA therapy for >12 months and analyzed the kinetic patterns through group-based trajectory models (GBTMs).
Results
The median treatment duration for the entire cohort was 60.3 months. GBTMs revealed 4 patterns in patients achieving HBsAg loss (groups 1–4) in the study population and in patients achieving HBsAg <100 IU/mL among those with HBeAg-negative CHB with baseline HBsAg ≥100 IU/mL (groups A–D). Patients in groups 1 and A had the highest rates of HBsAg loss (22.2%, 6/27) and of achieving HBsAg <100 IU/mL (47.5%, 56/118), respectively. HBsAg <40 IU/mL and <400 IU/mL at 12 months of treatment predicted group 1 and group A membership among all patients and those with HBeAg-negative CHB, respectively. Multivariable Cox regression analysis identified HBsAg trajectory group (group 1 vs groups 3 and 4: hazard ratio [HR], 179.46; P < .001; group 2 vs groups 3 and 4: HR, 24.34; P < .001) and HBsAg decline (HR, 82.14; P < .001) as independent predictors of both HBsAg loss and achieving HBsAg <100 IU/mL.
Conclusions
Serum HBsAg trajectories and decline can predict HBsAg loss and the achievement of HBsAg <100 IU/mL in patients with CHB receiving long-term NA therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
- Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan.
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
- School of Medicine, China Medical University, Taichung, Taiwan.
ORCID-Profile: Wei-Fan Hsu, Cheng-Yuan Peng
Förderung
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Hsu, W. F., Chen, C. F., Lai, H. C., Su, W. P., Wang, H. W., Chen, S. H., Huang, G. T., & Peng, C. Y. (2024). Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B. Open Forum Infectious Diseases, 11(12). https://doi.org/10.1093/ofid/ofae699
Vancouver
Hsu WF, Chen CF, Lai HC, Su WP, Wang HW, Chen SH, et al. Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B. Open Forum Infectious Diseases. 2024;11(12). doi:10.1093/ofid/ofae699
BibTeX
@article{Hsu2024,
author = {Hsu, Wei-Fan and Chen, Chuen-Fei and Lai, Hsueh-Chou and Su, Wen-Pang and Wang, Hung-Wei and Chen, Sheng-Hung and Huang, Guan-Tarn and Peng, Cheng-Yuan},
title = {Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {12},
doi = {10.1093/ofid/ofae699}
}
EUVIMED